SAN FRANCISCO, Nov. 17 Medivation, Inc.(Nasdaq: MDVN) today announced that new data about the mechanism of action ofDimebon, its lead product candidate in development to treat Alzheimer's andHuntington's diseases, will be presented at upcoming scientific conferences:
Results from the first pivotal trial of Dimebon in Alzheimer's diseaseshowed that patients treated with Dimebon experienced statisticallysignificant improvements compared to placebo in key aspects of the disease --memory and thinking, activities of daily living, behavior and overallfunction. Dimebon's benefit over placebo continued to increase throughout the12-month treatment period. At the end of 12 months, Dimebon-treated patientswere on average functioning as well or better than they had been at the startof the study on each of 5 clinical endpoints. These results were published inthe July 19, 2008, edition of The Lancet.
In July 2008, Medivation announced positive safety and efficacy resultsfrom its Phase 2 trial of Dimebon in Huntington's disease. Dimebon appearedto be well tolerated and showed statistically significant benefit versusplacebo in cognition as measured by the Mini-Mental State Examination, asecondary endpoint in the study.
Medivation, Inc. is a biopharmaceutical company focused on the rapiddevelopment of novel small molecule drugs to treat serious diseases for whichthere are limited treatment options. Medivation aims to transform thetreatment of these diseases and offer hope to critically ill patients andtheir caregivers. The Company's current clinical development program includesa pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease anda Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant(also known as hormone-refractory) prostate cancer. Medivation recentlyannounced that it plans to continue further development of Dimebon in patientswith mild-to-moderate Huntington's disease based on the positive results seenin its Phase 2 trial. In September 2008, Medivation entered into a globalagreement with Pfizer Inc to develop and commercialize Dimebon for thetreatment of Alzheimer's and Huntington's diseases. For more information,please visit us at http://www.medivation.com.
This press release contains forward-looking statements, includingstatements regarding the mechanism of action of Dimebon, the potentialbenefits of Dimebon as a treatment for Alzheimer's disease and Huntington'sdisease and future clinical development plans and milestones, which are madepursuant to the safe harbor provisions of the Private Securities LitigationReform Act of 1995. Any statements contained in this press release that arenot statements of historical fact may be deemed to be forward-lookingstatements. Forward-looking statements involve risks and uncertainties thatcould cause Medivation's actual results to differ significantly from thoseprojected, including, without limitation, risks related to progress, timingand results of Medivation's clinical trials, difficulties or delays inobtaining regulatory approval, enrollment of patients in Medivation's clinicaltrials, partnering of Medivation's product candidates, including Medivation'scollaborative relationship with Pfizer, manufacturing of Medivation's productcandidates, competition with Medivation's product candidates should theyreceive marketing approval, the adequacy of Medivation's financial resources,unanticipated expenditures or liabilities, intellectual property matters, andother risks detailed in Medivation's filings with the Securities and ExchangeCommission, including its quarterly report on Form 10-Q filed on November 10,2008 with the SEC. You are cautioned not to place undue reliance on theforward-looking statements, which speak only as of the date of this release.Medivation disclaims any obligation or undertaking to update or revise anyforward-looking statements contained in this press release.Conference: Society for Neuroscience's "Neuroscience 2008" Location/Date: Washington, D.C., November 15-19 Abstract Title: Dimebon Induces Neurite Outgrowth and Mitochondrial Stabilization Poster Presentation Date: Tuesday, November, 18, 8:00 a.m. EST Presenter: Andrew Protter, Ph.D., vice president, preclinical development for Medivation Conference: Cold Spring Harbor Laboratory's "Neurodegenerative Diseases: Biology & Therapeutics" Location/Date: Cold Spring Harbor, N.Y., December 4-7 Abstract Title: Dimebon Induces Neurite Outgrowth and Stabilization in the Setting of Cell Stress Presentation Date: Saturday, December 6 Presenter: Andrew Protter, Ph.D., vice president, preclinical development for Medivation
SOURCE Medivation, Inc.